Side-by-side · Research reference

ChonlutenvsDihexa

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED8/38 cited

BAnimal-StrongHUMAN-REVIEWED7/28 cited

Chonluten

Khavinson Bioregulator · Bronchial Mucosa

BronchialTarget tissue

In vitroEvidence tierAvolio 2022

THP-1Model systemAvolio 2022

Oral · Sublingual · Per Protocol

Dihexa

Angiotensin IV Analogue · Pre-Clinical

Pre-clinicalDevelopment stage

Rodent onlyEvidence basisBenoist 2014

HGF/c-MetTarget systemWright 2015

Not established — animal studies only

01Mechanism of Action

Parameter

Chonluten

Dihexa

Primary target

Bronchial epithelial cells and respiratory mucosa tissue complexes

c-Met receptor (HGF receptor tyrosine kinase)

Pathway

Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022

HGF/c-Met receptor activation → downstream signaling cascade → synaptogenesis and dendritic arborization

Downstream effect

Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022

Induction of dendritic arborization, synapse formation, neurogenesis, and neuroprotection in rodent models

Feedback intact?

—

Origin

Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology

Small-molecule angiotensin IV analogue designed to activate HGF/c-Met systemWright 2015

Antibody development

—

02Dosage Protocols

Parameter

Chonluten

Dihexa

Typical protocol dose

10–20 mg / day

Russian bioregulator tradition dosing; not standardized in Western literature.

—

Frequency

Once or twice daily

—

Route

Oral (capsule) or sublingual

Sublingual claimed for enhanced bioavailability; not validated.

—

Evidence basis

In vitro mechanistic

Pre-clinical / Rodent models

Duration

10–30 days per cycle

Traditional Khavinson protocol; cyclic administration common.

—

Clinical validation

None (PubMed indexed)

—

Human dosing

—

Not established — no human trials

Animal studies

—

Mouse/rat models only — dosing not translatable to humans

Clinical status

—

No Phase 1, 2, or 3 trials published

04Side Effects & Safety

Parameter

Chonluten

Dihexa

Documented adverse events

No published safety data in PubMed-indexed literature

—

Theoretical risks

Peptide hypersensitivity, GI intolerance (uncharacterized)

—

Drug interactions

Unknown — no pharmacokinetic studies available

—

Pregnancy / lactation

No data — avoid

—

Human safety data

—

None available — no human clinical trials

Theoretical c-Met risks

—

c-Met receptor activation has been implicated in tumorigenesis; unknown cancer risk profile

Pre-clinical tolerability

—

Not systematically reported in available studies

Absolute Contraindications

Chonluten

·Known hypersensitivity to peptide components

Dihexa

·Not approved for human use — research compound only

Relative Contraindications

Chonluten

·Pregnancy and lactation (insufficient data)
·Active malignancy (theoretical bioregulator concern)

Dihexa

·Theoretical contraindication: active or history of malignancy (c-Met pathway involvement in cancer)

05Administration Protocol

Parameter

Chonluten

Dihexa

1. Preparation

Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.

No established protocol. Dihexa has not been tested in human subjects. Animal studies used various routes (typically subcutaneous or intraperitoneal in rodents) not translatable to clinical use.

2. Oral route

Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.

Pre-clinical research compound. Not approved by FDA or any regulatory authority for human use.

3. Sublingual route

Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.

—

4. Timing

Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.

—

5. Cycle protocol

10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.

—